OncoDxRx's PGA Test Signposts Personalized Treatments
The one-of-a-kind PGA test will likely remain a significant player in global precision medicine for the foreseeable future.
- (1888PressRelease) January 07, 2024 - Exploring OncoDxRx’s PGA: A Quick Rundown
OncoDxRx’s PGA (Patient-derived Gene expression-informed Anti-cancer drug efficacy) is a pivotal multi-biomarker test developed by the liquid biopsy company OncoDxRx. Known for its exclusiveness, PGA is developed to support clinical decision-making, especially for those non-responder patients.
Introduction: PGA is a masterpiece of modern molecular diagnostics, encompassing leading-edge proprietary technologies with exceptional performance. PGA is unique in its ability to screen, match, and identify effective anticancer drugs in a single run, significantly decreasing the cost and turnaround time, which helps in streamlining operations and workflows for its operators.
Design and Features: The PGA’s design emphasizes its dry- and wet-lab capabilities, meaning it can undertake multiple tasks during a single analysis. It features gene expression panels with biomarkers representing various cancer pathways. The technology is equipped with a state-of-the-art analytical suite, including cell-free mRNA (cfmRNA) panel profiling, and an in silico computation which offers high predictive power of drug efficacy.
Operational Capabilities: PGA’s power comes from OncoDxRx’s cfmRNA expertise, experience and knowhow, which give it superior performance – the capability to sustain high throughput and accuracy. Its wide range of drug screening targets more than 700 compounds, including FDA and globally approved drugs, clinical trial drugs, and pre-clinical compounds, among others.
Global Impact and Export: OncoDxRx has not only been a leader in liquid biopsy cfmRNA field but has also gained international recognition. The PGA’s success on the precision oncology market underscores the global appetite for transformative molecular diagnostics.
Recent Developments: PGA is continually being upgraded to incorporate the latest datasets, and being expanded to cover other cancer types. The latest upgrade including PGA Lung, PGA Breast, and PGA Pancreatic.
Conclusion: PGA stands as a testament to OncoDxRx’s cfmRNA expertise, offering unmatched adaptability and performance. Its design philosophy ensures it can evolve with emerging technologies, thus future-proofing the testing workflow and its capabilities. The one-of-a-kind PGA will likely remain a significant player in global precision medicine for the foreseeable future.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam